Codexis. has been granted a patent for engineered ketoreductase polypeptides that facilitate the production of phenylephrine. The patent specifically claims a polypeptide with at least 95% sequence identity to a specified sequence, incorporating specific amino acid modifications. GlobalData’s report on Codexis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Codexis, Bioethanol production GMOs was a key innovation area identified from patents. Codexis's grant share as of June 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Engineered polypeptides for producing phenylephrine
The patent US12031159B2 describes an engineered polypeptide designed to convert 1-(3-hydroxyphenyl)-2-(methylamino)ethanone into (R)-phenylephrine. This polypeptide exhibits at least 95% identity to a specified amino acid sequence (SEQ ID NO: 4) and includes specific residue variations, such as C190G, A202F, M206C, and Y249F. The engineered polypeptide is noted for its ability to perform this conversion with a high degree of stereospecificity, achieving an enantiomeric excess of at least 99%. Additionally, the patent includes claims for an engineered polynucleotide that encodes this polypeptide.
The patent further outlines a method for producing (R)-phenylephrine from the specified substrate, detailing the reaction conditions necessary for optimal conversion. These conditions include maintaining a temperature range of approximately 25°C to 35°C, with a preferred temperature of around 30°C, and a pH level between 6.5 and 7.0. The method also specifies the use of a buffer, such as triethanolamine or potassium phosphate, and the inclusion of 50% isopropyl alcohol in the reaction mixture. Other parameters include the presence of NADP and conducting the reaction under an inert atmosphere, specifically nitrogen. The comprehensive conditions aim to facilitate the conversion process over a duration of 19 to 24 hours, ensuring effective synthesis of (R)-phenylephrine.
To know more about GlobalData’s detailed insights on Codexis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
